Our company has a proprietary and complete S2 recombinant protein technology base – ExpreS2, which was developed over ten years at Pharmexa A/S. We have in-depth practical experience with the non-viral Drosophila S2 expression technology for the production of recombinant proteins for preclinical development and for use in clinical trials.
By leveraging our ability to express malaria parasite proteins with ExpreS2 a cGMP-compatible system, we have enabled progress of malaria vaccine candidates into clinical research. ExpreS2ion Biotechnologies is working with top academic teams to advance vaccines directed at different malaria stages of infection: blood stage malaria and pregnancy malaria.
ExpreS2ion Biotechnologies specializes in establishment of high-producing cell lines together with upstream process development and working with customers to solve technical problems in molecular biology, protein expression or other issues relating to S2 cells. S2 related reagents are also available.
NEWS / EVENTS
October 2013 : ExpreS2ion Biotechnologies is a Nordic Star: selected by the hosts to Nordic Life Sciences Days, which took place in Stockholm, October 14-15... Continue reading
October 2013 : ExpreS2ion Biotechnologies is again sponsoring the 14th Annual World Vaccine Congress, taking place in France, October 16-17... Continue reading
August 2013 : ExpreS2ion Biotechnologies welcomes Thomas Joergensen, MSc., who will support both up- and downstream development... Continue reading
An article on the June 2013 issue of Pharmaceutical Bioprocessing reviews the applications of S2 cells in research and the clinic. Read the article here
ExpreS2 protein expression platform is licensed to Cancer Research UK’s Protein Purification Facility Read the PR here
EU funding for clinical trials of a placental malaria vaccine
Read the article here